Timing of antiretroviral drugs during tuberculosis therapy [1]

New England Journal of Medicine

Volumn 362, Issue 22, 2010, Pages 2137-2139

  Wilson, Douglas ^a   Meintjes, Graeme ^b  

^a EDENDALE HOSPITAL   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MORTALITY; PRIORITY JOURNAL; TUBERCULOSIS; THERAPY DELAY; TREATMENT OUTCOME; AIDS RELATED COMPLEX; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; NOTE;

ANTIRETROVIRUS AGENT; EFAVIRENZ; TUBERCULOSTATIC AGENT;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; TUBERCULOSIS;

EID: 77953150422     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1003767     Document Type: Letter

References (5)

1. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362:697-706.
2. Connolly C, Davies GR, Wilkinson D. Impact of the human immunodeficiency virus epidemic on mortality among adults with tuberculosis in rural South Africa, 1991-1995. Int J Tuberc Lung Dis 1998;2:919-925
3. van den Broek J, Mfinanga S, Moshiro C, O'Brien R, Mugomrla A, Lefi M. Impact of human immunodeficiency virus infection on the outcome of treatment and survival of tuberculosis patients patients in Mwanza, Tanzania. Int J Tuberc Lung Dis 1998;2:547-552 (Pubitemid 28320061)
4. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005;5:361-373
5. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006;58:1299-1302 (Pubitemid 44884158)